Albuked Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Albuked market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the rising prevalence of medical conditions, the expansion of therapeutic applications, increased demand in emerging markets, the growing aging population, and advancements in plasma fractionation technology.

The projected growth during the forecast period can be attributed to the rising prevalence of chronic diseases, increased awareness among healthcare professionals, growing demand, the expansion of critical care units, and heightened awareness within the healthcare community. Key trends expected in this period include the growth of recombinant albumin, dominance of the therapeutics segment, rising demand for diagnostics, a shift towards drug delivery systems, and emerging market opportunities.

The rising incidence of liver disorders is expected to drive the growth of the albuked market in the coming years. Liver disorders encompass a wide range of conditions that impact liver function, such as hepatitis, cirrhosis, fatty liver disease, and autoimmune diseases. The increasing prevalence of liver disorders is attributed to factors including excessive alcohol consumption, obesity, viral infections, exposure to toxins, and genetic predispositions that compromise liver health. Albuked is used to manage liver disorders, particularly acute liver failure, by supporting colloid osmotic pressure and binding excess bilirubin in patients with rapid liver function loss. This may help prevent complications such as coma. For example, the American Liver Foundation reported in September 2023 that over 100 million people in the U.S. are affected by some form of liver disease. Among them, 4.5 million adults (1.8%) have been formally diagnosed, and an estimated 80-100 million adults in the U.S. have fatty liver disease, many of whom are unaware of their condition. Furthermore, the Journal of Hepatology highlighted in August 2023 that liver disease is responsible for over 2 million deaths annually, accounting for about 4% of all global deaths, with one-third of these deaths occurring in women. Liver cancer alone causes between 600,000 and 900,000 deaths each year. The increasing incidence of liver disorders is therefore driving the demand for treatments like albuked.

A key trend in the albuked market is the development of advanced therapies, such as human albumin injection therapy, to address critical medical conditions. Human albumin injection therapy involves the use of human serum albumin (HSA), a protein derived from human plasma, to treat a range of conditions. This therapy is commonly employed in clinical settings to manage hypoalbuminemia, liver cirrhosis, trauma, burns, and fluid resuscitation during surgeries. For instance, in July 2023, Grifols S.A., a Spain-based manufacturer of plasma-derived medicines, announced the completion of Phase 3 of the PRECIOSA study. The clinical trial aims to assess the long-term effectiveness of albumin-based treatments, specifically Grifols’ Albutein, in extending the survival time of patients with decompensated cirrhosis and ascites until a suitable transplant becomes available.

In June 2023, Kedrion Biopharma, a US-based biopharmaceutical company, formed a partnership with Bio Products Laboratory (BPL) to increase the availability of plasma-derived therapies in China. The collaboration focuses on expanding the supply of plasma-derived therapies, particularly human albumin, in the Chinese market. BPL, a UK-based pharmaceutical company, specializes in the manufacture and distribution of plasma-derived products for healthcare professionals and patients.

The key players operating in the albuked market is Kedrion Biopharma Inc.

North America was the largest region in the albuked market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the albuked market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Albuked is a recombinant human albumin-based therapeutic protein primarily used to treat hypoalbuminemia, a condition characterized by abnormally low albumin levels in the blood. Produced through genetic engineering, it is utilized in various medical conditions, including liver cirrhosis, nephrotic syndrome, and burns. Albuked helps replenish albumin levels in the bloodstream, maintaining fluid balance, improving circulation, and preventing complications associated with protein deficiencies. As a synthetic alternative to plasma-derived albumin, it is typically administered intravenously under medical supervision.

The main formulations of albuked include Albuked 5%, Albuked 25%, Plasbumin-5, and Plasbumin-25. Albuked 5% is specifically designed for therapeutic use in managing conditions like hypovolemia and hypoalbuminemia. Its clinical indications include hypovolemic shock, hypoproteinemia, acute respiratory distress syndrome (ARDS), cardiopulmonary bypass, and acute liver failure. Albuked is available in packaging sizes of 50 ml, 250 ml, and 500 ml. It is distributed through hospitals, clinics, and both retail and specialty pharmacies, and is used by various end users, including adult and geriatric patients.

The albuked market research report is one of a series of new reports that provides albuked market statistics, including albuked industry global market size, regional shares, competitors with a albuked market share, detailed albuked market segments, market trends and opportunities, and any further data you may need to thrive in the albuked industry. This albuked market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The albuked market consists of sales of Albuminar-5, Albuminar-25, and Buminate. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.